Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861

Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study for its drug candidate, called NMRA-861.

The study is being conducted in healthy adult participants and adults with stable schizophrenia. In preclinical studies, NMRA-861 demonstrated a strong pharmacological profile and was found to be safe and well-tolerated.

Neumora expects to report data from the Phase 1 SAD/MAD study in the first quarter of 2026. This data will include assessments of the drug’s safety, tolerability, and human pharmacokinetic data, which will confirm its potential for once-daily dosing and central nervous system penetration.

Neumora Therapeutics Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company that develops therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the US.

While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.